Wendy Armstrong, MD, FIDSA is Professor of Medicine/Infectious Diseases and the Division Head at the University of Colorado School of Medicine. Her research interests are in innovative methods of care delivery to vulnerable populations living with HIV and in expanding the ID/HIV workforce. She has published more than 100 journal articles and book chapters related to these topics. She is the President-elect for the Infectious Disease Society of America and is a past Chair of the HIV Medicine Association.

Paul G Auwaerter is the Sherrilyn and Ken Fisher Professor of Medicine at the Johns Hopkins University School of Medicine and Director of the Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases.

He serves as the Executive Director of the Johns Hopkins Point of Care-Information Technology (POC-IT) Center, producing the Johns Hopkins Antibiotic Guide (ABX), JH HIV, JH Osler, JH Psychiatry, and JH Diabetes Guides. Dr. Auwaerter serves as Editor-in-Chief of the ABX Guide. Over the last 20 years, it has become a standard reference for ID-related clinical decision support and rational antimicrobial management. Dr. Auwaerter’s research and clinical interests include improving the diagnosis, care, and prevention of Lyme disease and other tick-borne infections, as well as fevers of unknown origin, surgical infections, Epstein-Barr virus, and antibiotic resistance. He has published over 125 articles and 30 textbook chapters.

He has served for 19 years as the Clinical Director of the Johns Hopkins Division of Infectious Disease. He is also a Past President of the Infectious Diseases Society of America (IDSA), the largest professional society worldwide related to infectious diseases. In 2025, Dr. Paul Auwaerter received the University’s Inaugural Osler Award for Clinical Excellence, recognizing his contributions to patient care, education, and innovation at Johns Hopkins.

Dr Isaac Bogoch is a Professor at the University of Toronto in the Department of Medicine, and an Infectious Diseases specialist at the Toronto General Hospital with a focus on tropical diseases, HIV, and general infectious diseases. He completed medical school and Internal Medicine residency training at the University of Toronto, and then specialized in Infectious Diseases at Harvard University. He holds a Master’s Degree in Epidemiology from the Harvard School of Public Health, and has completed fellowships in both Tropical Infectious Diseases and HIV care. Dr. Bogoch works at the intersection of clinical medicine, epidemiology, public health, health security and policy. He divides his clinical and research efforts between Toronto and several countries in Africa and Asia. His work focuses on reducing the impact of emerging infectious diseases like mpox, viral hemorrhagic fevers, and HIV, while also developing strategies to enhance the quality of medical care in low-resource settings.

Helen Boucher, MD, is the Dean and Professor of Medicine at Tufts University School of Medicine and Chief Academic Officer of the Tufts Medicine Health System. An active Infectious Diseases physician, she was previously Chief of the Division of Geographic Medicine and Infectious Diseases at Tufts Medical Center, and Director of the Stuart B. Levy Center for Integrated Management of Antimicrobial Resistance (Levy CIMAR).

Dr Boucher’s clinical interests include infections in immunocompromised patients and S. aureus infections. Her research interests focus on S. aureus and the development of new anti-infective agents. She is the Chair of the National Institutes of Health Antibacterial Resistance Leadership Group Innovations Working Group and serves on the Executive and Steering Committees. Dr. Boucher is the published in such journals as The New England Journal of Medicine, Antimicrobial Agents and Chemotherapy, Clinical Infectious Diseases, and The Annals of Internal Medicine. She previously served as Editor of Antimicrobial Agents and Chemotherapy, and currently is Editor of the Sanford Guide to Antimicrobial Therapy, and Infectious Diseases Clinics of North America.

In 2015, Dr. Boucher was appointed a voting member of the Presidential Advisory Council on Combating Antibiotic Resistant Bacteria (PACCARB), and elected Treasurer of the Infectious Diseases Society of America (IDSA). She was awarded the IDSA Society Citation Award in October 2015 and the Maxwell Finland Award in 2022. In 2023, she became an Honorary Fellow, Royal College of Physicians of Ireland the highest award the Royal College of Physicians of Ireland can confer. Dr. Boucher serves as Chair of the Board of Trustees of The College of the Holy Cross is a member of the Physicians of Tufts Medical Center.

Charles L. Daley, MD, is Chief of the Division of Mycobacterial and Respiratory Infections at National Jewish Health (NJH) and Professor of Medicine at NJH, the University of Colorado School of Medicine, and Icahn School of Medicine at Mount Sinai. Dr. Daley has served on and chaired expert panels for the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), Infectious Diseases Society of America and American Thoracic Society. He chaired the multi-society sponsored revision of the guidelines for the treatment of pulmonary nontuberculous mycobacterial infections. For his work with global MDR-TB control he was awarded the World Lung Health Award by the American Thoracic Society. He was previously Associate Editor of the American Journal of Respiratory and Critical Care Medicine and The European Respiratory Journal and is now Associate Editor for Frontiers in Tuberculosis. His academic interests include clinical and translational research related to TB, NTM and bronchiectasis.

Carlos del Rio, MD is the H. Cliff Sauls, MD Distinguished Professor of Medicine and Chair of the Department of Medicine at Emory University School of Medicine. He is also Professor of Global Health and Epidemiology at the Rollins School of Public Health. Dr. del Rio is co-Director of the Emory Center for AIDS Research and co-PI of the Emory Vaccine and Treatment Evaluation Unit. A native of Mexico where he attended medical school graduating with honors in 1983. He did his Medicine and Infectious Diseases training at Emory. In 1989 he returned to Mexico where he was Executive Director of the National AIDS Council. In 1996 Dr. del Rio returned to Emory where he is involved in patient care, teaching and research. Dr. del Rio has had multiple leadership positions at Emory including Chief of the Emory Medical Service at Grady Memorial Hospital (2001 – 2009), chair of the Hubert Department of Global Health (2009 – 2019), Executive Associate Dean for Emory at Grady (2019 – 2023) and interim Dean of Emory University School of Medicine (2023 – 2024). Dr. del Rio’s research focuses on the early diagnosis, access to care, engagement in care, compliance with antiretrovirals and the prevention of HIV infection. He has worked for over a decade with hard-to-reach populations including with persons who use substances to improve outcomes of those infected with HIV and to prevent infection with those at risk. He is also interested in the translation of research findings into practice and policy. His international work includes collaborations in the country of Georgia, Ethiopia, Vietnam, Mexico, Kenya and Thailand. He has also worked on emerging infections such as pandemic influenza and was a member of the WHO Influenza A(H1N1) Clinical Advisory Group and of the CDC Influenza A(H1N1) Task Force during the 2009 pandemic. He is the Immediate Past President of the Infectious Diseases Society of America and the past chair of the PEPFAR Scientific Advisory Committee. del Rio was elected to the National Academy of Medicine in 2013 and elected as the Academy’s International Secretary in 2020 and reelected in 2024. He was also elected to the American Academy of Arts and Sciences in 2022. During the COVID-19 pandemic Dr. del Rio was a leader locally and nationally, doing research, developing policies, writing scientific publications, and making countess media appearances. Dr. del Rio advised municipal, state, and national leaders and also served on the national advisory committee of the COVID Collaborative, which focuses on developing consensus recommendations and engaging with U.S. leaders on effective policy and coronavirus response. Dr. del Rio was named as one of the “50 most trusted experts” and recognized by the HHS Secretary as a “Trusted Messenger”.

Dr Daniel Diekema is Vice Chair for Research and Director of the Division of Infectious Diseases in the Department of Medicine at Maine Medical Center in Portland, Maine. He is also a Professor Emeritus of Internal Medicine at the University of Iowa, where he served as a director for the Division of Infectious Diseases from 2010-2021. Dr. Diekema received his MD at Vanderbilt University in 1989. He did his residency in internal medicine at the University of Virginia (1989-1992). He did his fellowships in infectious diseases (1992-1995) and medical microbiology (1998-2000) at the University of Iowa. Also while at the University of Iowa, he received his master of science in preventive medicine. As a hospital epidemiologist, infectious diseases clinician and a clinical microbiologist, Dr. Diekema has studied and published extensively on the epidemiology of antimicrobial resistance and health care-associated infections. Dr. Diekema is a past president of the Society for Healthcare Epidemiology of America, and was also a member and co-chair of the CDC Healthcare Infection Control Practices Advisory Committee.

Dr Goff is an Infectious Diseases Clinical Pharmacist, Professor of Pharmacy Practice and Antibiotic Stewardship Ambassador for The Ohio State University (OSU) Global One Health Institute in Columbus Ohio, USA. She is an awarding winning global “change maker” in infectious diseases. Dr. Goff is one of twenty-five global health experts selected by the World Health Organization (WHO) to implement antibiotic stewardship programs in low middle-income countries. Dr. Goff is the Program Director for the Train the Trainer Antibiotic Stewardship Mentoring Program founded in 2012 with South African pharmacists. Her program continues to expand to include neonatal ASP and other countries including Lebanon and six Latin American countries in collaboration with country experts and neonatal experts at Nationwide Children’s Hospital in Columbus OH. She received the OSU 2019 Distinguished International Outreach and Engagement Award for her global work and the 2017 American College of Clinical Pharmacy Global Health Award. Dr. Goff is the Principal Investigator on the first US study with private practice dentists to assess their antibiotic use and provide guidance on the use of antibiotics in dentistry. Dr. Goff speaks to dental study clubs, dental schools, the FDI World Dental Federation and US Dental CE Academy providing antibiotic stewardship education to over 3,800 dental providers in over 80 countries. Her TEDx talk titled antibiotics “just in case” there’s infection has over 28,500 views on YouTube. She uses X (Twitter) (@idpharmd) to connect with her 10,000 followers. She has 150 publications and 50 grants.

Dr Andy Hale received his undergraduate education at Middlebury College, then went to medical school at Tufts University School of Medicine. He completed internal medicine residency, chief residency, and infectious diseases fellowship at Beth Israel Deaconess Medical. He is now an associate professor and ID physician at the University of Vermont Medical Center. He is the course director of cardiac, respiratory, and renal pathophysiology at UVM College of Medicine, Infectious Diseases: past, present, and future at Middlebury College, and Comparative Physiology at Mount Desert Island Biological Laboratory. He is an associate program director for the internal medicine residency at UVM. His main research interests are pragmatic studies to answer common clinical dilemmas in ID.

Dr Kimberly Hanson is a Professor of Medicine and Pathology at the University of Utah (U of U). Administratively, she serves as the Director of the Immunocompromised Host Infectious Diseases Service for U of U Health and is Director of the Mycology Section within ARUP Laboratories. Her clinical and research interests involve the development and validation of novel diagnostic tests with a focus on opportunistic infections.

Dr Carl LeBuhn completed medical school, internal medicine residency, chief residency, and infectious diseases fellowship at the University of Iowa. He spent three years on the teaching faculty at the University of Iowa before entering private practice in Paducah, Kentucky in June of 2000. For the past 21 years he has has provided inpatient and outpatient general infectious diseases consultations for western Kentucky and southern Illinois. He has clinical privileges at Baptist Health Paducah, ContinueCare Hospital at Baptist Health Paducah, and Mercy Health Paducah. He and his partner provide HIV/AIDS care to approximately 400 patients through LivWell a federally funded HIV/AIDS organization. He is currently the chair of the Paducah Independent Schools Board of Education and has served on the Board since 2005.

Dr Marrazzo was appointed as the Chief Executive Officer of the Infectious Disease Society of America in January, 2026. She was the sixth Director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health (2023-2025), and previously was Professor of Medicine and Director of the Division of Infectious Diseases at the University of Alabama at Birmingham School of Medicine. She was elected to the National Academy of Medicine in 2024. She has a broad research portfolio that includes the relationships between the vaginal microbiome and female reproductive tract infections, HIV pre-exposure prophylaxis, hormonal contraception, and risk of STI/HIV acquisition.

Dr. Pavia received his bachelor's degree and medical degree at Brown University. He trained in internal medicine and pediatrics at Dartmouth and the University of Utah. At the Centers for Disease Control and Prevention, Dr. Pavia trained in Public Health Epidemiology as an Epidemic Intelligence Service (EIS) officer and a Preventive Medicine Resident. Additionally, Dr. Pavia completed a fellowship in pediatric and adult infectious diseases at the University of Utah. He joined the faculty at the University of Utah in 1991. In 2003 Dr. Pavia became the George and Esther Gross Presidential Professor and Chief of the Division of Pediatric Infectious Diseases, where he mentors a dynamic and productive team of faculty and fellows. He also serves as Director of Hospital Epidemiology at Primary Children's Hospital and Associate Director of Antimicrobial Stewardship. Dr. Pavia is a member of the Society for Pediatric Research. He is a Fellow of the American Academy of Pediatrics, the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Dr. Pavia is a member of the National Academy of Science Engineering and Medicine Forum on Preparedness. He was recently Vice Chair and Chair of the Program Committee for IDWeek and served two terms on the CDC Board of Scientific Counselors. He has served as a member of the Board of Directors the Infectious Disease Society of America (IDSA) and past chair of the Pandemic Influenza Task Force and past Chair of the National and Global Public Policy Committee. Dr. Pavia served as a member of the National Vaccine Advisory Committee and chaired the Vaccine Safety Working Group, was an inaugural member of the National Biodefense Science Board (NBSB) and chaired the Influenza Working Group, and co-chaired the Personal Preparedness Working Group of the NBSB from 2008-2010. Dr. Pavia has served on several Institute of Medicine Committees including “Antivirals for Pandemic Influenza: Guidance on Developing and Distribution and Dispensing System,” and “Prepositioned Medical Countermeasure for the Public,” and is a frequent consultant for CDC. He is an associate Editor of the Sanford Guide to Antimicrobial Therapy and is on the editorial board the Journal of the Pediatric Infectious Disease Society and a reviewer for numerous journals. He has published more than 250 peer-reviewed scientific articles, textbook chapters, reviews and scientific abstracts. His research interests include the epidemiology of influenza and other emerging respiratory infections, pneumonia, vaccine preventable diseases, emerging infections, and HIV/ AIDS, with a particular interest in infections of pregnant women and their children. He has been the principal investigator or co-investigator on grants from the National Institutes of Health, the Bill and Melinda Gates Foundation, and the Centers for Disease Control and Prevention.

Dr. Pavia received his undergraduate and medical degrees from Brown University. He completed his residency at Dartmouth Hitchcock Medical Center and served as Chief Resident. He then served as an officer in the Epidemic Intelligence Service at the Centers for Disease Control and Prevention and completed a residency in Preventive Medicine. He completed fellowship training in pediatric and adult infectious diseases at the University of Utah. Dr. Pavia is currently the George and Esther Gross Presidential Professor at the University of Utah and is Chief of the Division of Pediatric Infectious Diseases. His academic interests include the epidemiology, diagnosis and management of emerging infectious diseases including influenza, respiratory infections and diarrheal diseases. He is also keenly interested in HIV/AIDS and has been involved in HIV clinical care and research since the 1980’s.

Dr Ilan Schwartz is an Associate Professor and Infectious Diseases physician and researcher at Duke University. His clinical focus is on preventing, diagnosing, and managing infections after transplantation, and his research focuses on dimorphic fungal pathogens. He serves on the Board of Directors of the Mycoses Study Group Education & Research Consortium and is an Editor of Clinical Infectious Diseases and Mycoses.

Dr Woodworth’s primary research interest is translational and clinical investigation of microbial therapeutics. Dr Woodworth's current projects are focused on use of fecal microbiota transplantation (FMT) to eradicate multidrug resistant organism (MDRO) colonization, use of next-generation sequencing analyses to query mechanisms of action of FMT, and leveraging population-level datasets to study risk factors and outcomes for infection with MDROs.